Description
Articles de périodiques scientifiques
Général
- Menopause in Cystic Fibrosis: Special considerations for bone health, menopausal symptoms, and treatmenton 26 mai 2025
Endocr Pract. 2025 Apr 28:S1530-891X(25)00129-6. doi: 10.1016/j.eprac.2025.04.011. Online ahead of print.ABSTRACTCystic fibrosis (CF) is a multisystem autosomal recessive disease arising from […]
- Harnessing Hypoxia: Bacterial Adaptation and Chronic Infection in Cystic Fibrosison 26 mai 2025
FEMS Microbiol Rev. 2025 May 1:fuaf018. doi: 10.1093/femsre/fuaf018. Online ahead of print.ABSTRACTThe exquisite ability of bacteria to adapt to their environment is essential for their capacity to […]
- Sex disparities in cystic fibrosis in the era of highly effective modulator treatment.on 26 mai 2025
BMC Pulmonary Medicine; 05/02/2025(AN 184914584); ISSN: 14712466CINAHL Complete
- 20 years of the Montreal Cystic Fibrosis Related Diabetes Screening Cohort: key insightson 26 mai 2025
Eur Respir Rev. 2025 May 14;34(176):240220. doi: 10.1183/16000617.0220-2024. Print 2025 Apr.ABSTRACTINTRODUCTION: The Montreal Cystic Fibrosis Related Diabetes Screening Cohort (MCFC) was established […]
- Managing an ageing cystic fibrosis population: challenges and prioritieson 26 mai 2025
Eur Respir Rev. 2025 May 14;34(176):240261. doi: 10.1183/16000617.0261-2024. Print 2025 Apr.ABSTRACTThe increasing life expectancy of people with cystic fibrosis (pwCF), largely driven by […]
Diagnostic et évaluation
- Guidelines for reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome and spinal muscular atrophyon 26 mai 2025
Pathology. 2025 Mar 26:S0031-3025(25)00123-0. doi: 10.1016/j.pathol.2025.02.004. Online ahead of print.NO ABSTRACTPMID:40318963 | DOI:10.1016/j.pathol.2025.02.004
- Pancreatic islet autoantibodies and their association with glycemic status in cystic fibrosis patients: A comprehensive meta-analysison 26 mai 2025
J Cyst Fibros. 2025 May 19:S1569-1993(25)01466-3. doi: 10.1016/j.jcf.2025.04.011. Online ahead of print.ABSTRACTBACKGROUND: The role of autoimmune beta-cell damage in cystic fibrosis-related glucose […]
- Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort studyon 22 avril 2025
Respir Med. 2025 Apr 4:108087. doi: 10.1016/j.rmed.2025.108087. Online ahead of print.ABSTRACTBACKGROUND: Diagnostic tests for cystic fibrosis (CF) are not readily available in resource-limited […]
- Imaging of cystic fibrosis manifestations in the abdomen.on 21 avril 2025
Abdominal Radiology; 05/01/2025Cystic fibrosis is a common inherited autosomal recessive disease affecting 35,000 persons in the United States. It is caused by mutations of the cystic fibrosis […]
- The role of islet CFTR in the development of cystic fibrosis-related diabetes: A semi-systematic reviewon 21 avril 2025
J Cyst Fibros. 2025 Apr 19:S1569-1993(25)00772-6. doi: 10.1016/j.jcf.2025.04.006. Online ahead of print.ABSTRACTBACKGROUND: Cystic fibrosis related diabetes (CFRD) is the most common comorbidity of […]
Interventions et traitements
- Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Managementon 26 mai 2025
Genes (Basel). 2025 Mar 30;16(4):402. doi: 10.3390/genes16040402.ABSTRACTCystic fibrosis (CF), a genetic disorder characterized by mutations in the CFTR gene, has seen significant advances in […]
- Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosison 26 mai 2025
Nat Med. 2025 Apr 29. doi: 10.1038/s41591-025-03678-8. Online ahead of print.ABSTRACTBacteriophage (phage) therapy, which uses lytic viruses as antimicrobials, is a potential strategy to address the […]
- Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Reviewon 26 mai 2025
Pharmacoeconomics. 2025 Apr 29. doi: 10.1007/s40273-025-01497-w. Online ahead of print.ABSTRACTBACKGROUND: Cystic fibrosis (CF) is a rare genetic condition requiring extensive medical care, which has […]
- Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosison 26 mai 2025
J Cyst Fibros. 2025 May 1:S1569-1993(25)01462-6. doi: 10.1016/j.jcf.2025.04.007. Online ahead of print.ABSTRACTBACKGROUND: Inhaled antibiotics are frequently used as chronic Pseudomonas aeruginosa […]
- Efficacy of Trikafta (ELX/TEZ/IVA) & Symdeko (TEZ/IVA) in Treating Cystic Fibrosis with F508del Allele: A Systematic Review and Meta-analysison 26 mai 2025
Thorac Res Pract. 2025 May 8. doi: 10.4274/ThoracResPract.2025.2025-1-1. Online ahead of print.ABSTRACTThe objective of the study was to assess and compare the efficacy of […]
- LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged 12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysison 26 mai 2025
J Cyst Fibros. 2025 May 15:S1569-1993(25)01467-5. doi: 10.1016/j.jcf.2025.04.012. Online ahead of print.ABSTRACTBACKGROUND: The cystic fibrosis (CF) transmembrane conductance regulator modulator […]
- Be it resolved airway clearance cannot and should not be replaced by exercise in the era of CFTR modulators-Summary of a Pro/Con debateon 26 mai 2025
J Cyst Fibros. 2025 May 16:S1569-1993(25)01468-7. doi: 10.1016/j.jcf.2025.05.001. Online ahead of print.ABSTRACTAirway clearance to clear excessive sputum has long been a key part of cystic fibrosis […]
- Population Pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a Real-World Cohort of Adults with Cystic Fibrosison 26 mai 2025
Clin Pharmacokinet. 2025 May 22. doi: 10.1007/s40262-025-01516-1. Online ahead of print.ABSTRACTBACKGROUND AND OBJECTIVES: Elexacaftor-tezacaftor-ivacaftor (ETI), a combination of cystic fibrosis […]
- Change in the 6-minute walk test among 71 patients with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftoron 26 mai 2025
Respir Med. 2025 May 23:108178. doi: 10.1016/j.rmed.2025.108178. Online ahead of print.ABSTRACTBACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) has led to substantial improvements in the clinical […]
Transplantation
- Characteristics and outcomes of people with cystic fibrosis on the Eurotransplant liver transplantation waiting liston 26 mai 2025
J Cyst Fibros. 2025 May 16:S1569-1993(25)00771-4. doi: 10.1016/j.jcf.2025.04.005. Online ahead of print.ABSTRACTBACKGROUND: Advanced cystic fibrosis (CF) liver disease can necessitate liver […]
- Impact of availability of a highly effective Cystic Fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the USon 26 mai 2025
Respir Med. 2025 May 21:108171. doi: 10.1016/j.rmed.2025.108171. Online ahead of print.ABSTRACTCystic fibrosis (CF) is a genetic disease that often leads to progressive lung disease and lung […]
- Prediction of Postoperative Lung Graft Dysfunction During the Procedure: A Single-Center Cohort Study of Cystic Fibrosis Patientson 26 mai 2025
J Cardiothorac Vasc Anesth. 2025 May 8:S1053-0770(25)00351-9. doi: 10.1053/j.jvca.2025.04.033. Online ahead of print.ABSTRACTOBJECTIVES: To predict severe primary graft dysfunction (PGD3) after […]
Nutrition et approches complémentaires
- The Effects of Progressive Muscle Relaxation on Mental Health and Sleep Quality in Adults with Cystic Fibrosis: A Randomized Controlled Trialon 26 mai 2025
J Clin Med. 2025 Apr 18;14(8):2807. doi: 10.3390/jcm14082807.ABSTRACTBackground/Objective: Cystic fibrosis (CF) is a chronic genetic disease affecting multiple body systems and having a significant […]
- Assessment of Dietary Intake in Adults with Cystic Fibrosis Pre and Post Commencement of Elexacaftor/Tezacaftor/Ivacaftoron 26 mai 2025
Clin Nutr ESPEN. 2025 Apr 24:S2405-4577(25)00274-8. doi: 10.1016/j.clnesp.2025.04.006. Online ahead of print.ABSTRACTBACKGROUND & AIMS: Elexacaftor, Tezacaftor, Ivacaftor has enhanced clinical […]
- The Role of Psychological Interventions in Enhancing Quality of Life for Patients with Cystic Fibrosis-A Systematic Reviewon 26 mai 2025
Healthcare (Basel). 2025 May 7;13(9):1084. doi: 10.3390/healthcare13091084.ABSTRACTBackground/Objectives: Cystic fibrosis (CF) is a chronic genetic disease that impacts both physical and […]
- Beyond the lungs: patients' experiences of musculoskeletal symptoms and manual therapy in cystic fibrosis care - A qualitative interview studyon 26 mai 2025
J Man Manip Ther. 2025 May 14:1-7. doi: 10.1080/10669817.2025.2505096. Online ahead of print.ABSTRACTBACKGROUND: Cystic fibrosis (CF) is a severe hereditary disease that affects multiple organ […]
Expériences des patients et des institutions
- Primary care physician involvement increases likelihood of cancer screening in people with cystic fibrosis: A population-based study from Ontario, Canadaon 26 mai 2025
J Cyst Fibros. 2025 Apr 26:S1569-1993(25)00770-2. doi: 10.1016/j.jcf.2025.04.004. Online ahead of print.ABSTRACTBACKGROUND: People with cystic fibrosis (pwCF) are living longer and with an increased […]
- [Translated article] Environmental impact of inhaled therapies in a cystic fibrosis unit: Strategies for sustainabilityon 26 mai 2025
Farm Hosp. 2025 Apr 26:S1130-6343(25)00009-1. doi: 10.1016/j.farma.2025.02.002. Online ahead of print.ABSTRACTOBJECTIVE: Inhaled therapy is essential in cystic fibrosis; however, inhalers have a […]
- "I think most people feel like healthcare professionals tell them to take their treatments and judge them for not taking them": reflexive thematic analysis of the views of adults with cystic fibrosis on how treatment adherence is discussed in healthcare.on 26 mai 2025
Psychology & Health; 05/01/2025Objective: Previous research exploring patient-practitioner communication in relation to adherence in cystic fibrosis (CF) is limited. This UK study explored the […]
- Living with cystic fibrosis during the COVID-19 pandemic: An interpretive description of healthcare access from patients with cystic fibrosis and their providers in Alberta, Canadaon 26 mai 2025
PLoS One. 2025 May 2;20(5):e0322911. doi: 10.1371/journal.pone.0322911. eCollection 2025.ABSTRACTBACKGROUND: The current study aimed to explore patient and provider perspectives of the impact of the […]
- Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME surveyon 26 mai 2025
J Cyst Fibros. 2025 May 3:S1569-1993(25)01465-1. doi: 10.1016/j.jcf.2025.04.010. Online ahead of print.ABSTRACTBACKGROUND: Despite widespread availability of modulator therapies and improved lung […]
- Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment.on 26 mai 2025
Journal of Patient-Reported Outcomes; 05/06/2025(AN 184978198); ISSN: 25098020CINAHL Complete
- Personal narratives to support learning about lung transplant for people with cystic fibrosison 26 mai 2025
Patient Educ Couns. 2025 May 5;137:108822. doi: 10.1016/j.pec.2025.108822. Online ahead of print.ABSTRACTOBJECTIVES: Cystic fibrosis (CF) causes progressive respiratory disease and premature death. […]
- Clinical Disorders in Cystic Fibrosis That Affect Emergency Procedures-A Case Report and Reviewon 26 mai 2025
J Clin Med. 2025 May 5;14(9):3187. doi: 10.3390/jcm14093187.ABSTRACTCystic fibrosis (CF) is a multisystemic disease caused by a genetic defect, namely a mutation in the CFTR gene, that results in the […]
- Integrating Case Management in Cystic Fibrosis Units: A Key to Enhancing Patient-Centered Care.on 26 mai 2025
Healthcare (2227-9032); 05/01/2025(AN 185126932); ISSN: 22279032CINAHL Complete
- Anticiper de futures crises : leçons de l’expérience patient mucoviscidose pendant la pandémie de COVID-19on 26 mai 2025
Sante Publique. 2025;37(1):209-223. doi: 10.3917/spub.251.0209.ABSTRACTINTRODUCTION: The care paths and lives of cystic fibrosis patients were profoundly altered during the health crisis in France. […]
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |